Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8658198 | OREXO US INC | Non-abusable pharmaceutical composition comprising opioids |
Dec, 2027
(4 years from now) | |
US8470361 | OREXO US INC | Non-abusable pharmaceutical composition comprising opioids |
May, 2030
(7 years from now) | |
US11020387 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
US10946010 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
US8940330 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
US9439900 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
US10874661 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
US9259421 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
US11433066 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) | |
US11020388 | OREXO US INC | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence |
Sep, 2032
(9 years from now) |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 July, 2013
Treatment: Sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone; Sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxo...
Dosage: TABLET;SUBLINGUAL
25
United States
4
Japan
4
European Union
3
Denmark
3
Slovenia
3
Portugal
3
Spain
3
Poland
2
Australia
2
Hong Kong
2
Croatia
2
Cyprus
2
RS
2
United Kingdom
2
New Zealand
1
Israel
1
South Africa
1
Mexico
1
Lithuania
1
Hungary
1
Singapore
1
Colombia
1
Brazil
1
Malaysia
1
Korea, Republic of
1
Peru
1
San Marino
1
Chile
1
China
1
EA
1
Canada
1
ME
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic